Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: allogenic CAR T cell therapies - Wugen

Next Previous
Search
Drug Profile

Research programme: allogenic CAR T cell therapies - Wugen

Alternative Names: Allogenic chimeric antigen receptor T cell therapies; UCART19 - Wugen; UCART2; UCART7

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WUGEN
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 02 Mar 2021 Wugen enters into exclusive license agreement with HCW Biologics for cell therapies for Cancer
  • 03 Dec 2018 Pharmacodynamics data from a preclincal trial in Haematological malignancies presented at 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top